Rational approach to the synthesis, evaluation, and 68Ga Labeling of a novel 4-anilinoquinoline epidermal growth factor receptor inhibitor as a new imaging agent that selectively targets the epidermal growth factor receptor tyrosine kinase

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 4, 2010, Pages 479-485

  Theeraladanon, Chumpol ^a   Takahashi, Nobukazu ^a   Shiina, Masaaki ^a   Hamada, Keisuke ^a   Takada, Yuuki ^a   Endo, Hisashi ^b   Tateishi, Ukihide ^a   Oka, Takashi ^a   Ogata, Kazuhiro ^a   Inoue, Tomio ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

imaging; molecular imaging; PET; radionuclide; site specific conjugation

Indexed keywords

(6,7 DIMETHOXYETHOXY) QUINOLIN 4 YL (3 ETHYNYLPHENYL) AMINE; 4 CHLORO 6,7 (BIS 2 METHOXYETHOXY) QUINOLINE; 4 CHLORO 6,7 DIOXYQUINOLINE; CHLORO 6,7 DIMETHOXYQUINOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GALLIUM 68; GLUTAMIC ACID POLYPEPTIDE (6,7 DIMETHOXYETHOXY) QUINOLIN 4 YL (3 ETHYNYLPHENYL) AMINE GA 68; PEROXIDASE; QUINOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YCU 05; YCU 07;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CAMERA; CANCER CELL CULTURE; CARCINOMA CELL; COLORIMETRY; COMPETITIVE INHIBITION; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONJUGATE; CONTROLLED STUDY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; INJECTION; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUDE MOUSE; PHARMACOPHORE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOACTIVITY; RING CLOSING METATHESIS;

AMINOQUINOLINES; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; GALLIUM RADIOISOTOPES; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 77956143095     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0614     Document Type: Article

References (20)

1. Woodburn JR. The Epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241.
2. Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science 1995;267:5205.
3. Bridges AJ, Zhou H, Cody DR, et al. Tyrosine kinase inhibitor. 8. An unusually steep structure-activity relationship for analogue of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 1996;39:267.
4. Rewcastle GW, Denny WA, Bridges AJ, et al. Tyrosine kinase inhibitor. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]-and 4-(phenylamino)quinazoline as potent adenosine 5?-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 1995;38:3482.
5. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265.
6. Shewchuk L, Hassell A, Wisely B, et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J Med Chem 2000;43:133.
7. Wissner A, Berger DM, Boschelli DH, et al. 4-Anilino-6,7- dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7- dialkoxyquinoline inhibitors. J Med Chem 2000;43:3244.
8. Theeraladanon C, Arisawa M, Nishida A, et al. A novel synthesis of substituted quinolines using ring-closing metathesis (RCM): Its application to the synthesis of key intermediates for anti-malarial agents. Tetrahedron 2004;60: 3017.
9. Kan T, Fukuyama T. Ns strategies: A highly versatile synthetic method for amines. Chem Commun 2004;4:353.
10. Arisawa M, Theeraladanon C, Nishida A, et al. Synthesis of substituted 1,2-dihydroquinolines and quinolines using eneene metathesis and ene-enol ether metathesis. Tetrahedron Lett 2001;42:8029.
11. Cheng K, Koland JG. Nucleotide binding by the epidermal growth factor receptor protein-tyrosine kinase. J Bio Chem 1996;271:311.
12. Farley K, Mett H, McGlynn E, et al. Development of solidphase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine protein kinase activity. Anal Biochem 1992;203:151.
13. Rodeck U, Herlyn M, Herlyn D, et al. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cellindependent effects. Cancer Res 1987;47:3692.
14. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cell. Nature 1984;309:418.
15. Takahashi N, Yang DJ, Kohanim S, et al. Targeted functional imaging of estrogen receptors with (99m)Tc-GAP-EDL. Eur J Nucl Med Mol Imaging 2007;34;354.
16. Piepsz A. Radionuclide studies in paediatric necphrourology. Eur J Radiol 2002;43:146.
17. Frennby B, Sterner G. Contrast media as markers of GFR. Eur Radiol 2002;12:475.
18. Clausen J, Edeling CJ, Fogh J. 67Ga binging to human serum proteins and tumor components. Cancer Res 1974; 34:1931.
19. Camargo EE, Wagner HN Jr., Tsan MF. Studies of gallium accumulation in inflammatory lesions: IV-Kinetics of accumulation and role of polymorphonuclear leukocyte in the distribution of gallium in experimental inflammatory exudates. Nucl Med 1979;19:147.
20. Brittenham GM. Disorders of iron metabolism: Iron deficiency and overload. In: Hoffman R, Benz EJ Jr., Shattil SJ, et al. (eds.), Hematology, Basic Principle and Practice. New York: Churchill Livingstone, 1991; 327.